Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies
Recruiting · NCT06907446 · Interventional (participants receive a specific treatment) · Lead sponsor: University of California, Davis
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
To study a novel biopsy needle system for performing transperineal prostate biopsy. Prostate biopsy remains the standard approach for prostate cancer detection. While pre-biopsy MRI allows for targeting of visible lesions, systemic or 'off target' samples are recommended due to the well-recognized risk of undegrading and under sampling with current commercially available needles. The SureCore plus single-use biopsy needle produces a more intact tissue core with a same caliber 18g needle with \~21% more tissue per core in pre-clinical studies. This research study will determine if a new biopsy needle designed to produce more robust tissue cores per sample can improve detection and characterization of prostate cancer.
Who can take part
Inclusion criteria
- Patient older than age of 18 undergoing prostate biopsy
Exclusion criteria
- Unable to consent
- Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives
- Prisoners
Where it is running
1 location listed across 1 US state.
- UC Davis Departments of Urologic Oncology - Sacramento, California, United States